by SMG Support | Mar 3, 2026 | Biotech Consulting, GMP Good Manufacturing Practices, Insights
Common GMP Mistakes That Lead to Form 483 Observations For biotech and pharmaceutical companies, Good Manufacturing Practice (GMP) compliance is non-negotiable. A Form 483 from the U.S. Food and Drug Administration can significantly disrupt operations, delay product...
by Jeffrey Wotton | Mar 3, 2026 | Biotech Consulting, Insights, Quality Control
Bridging the Gap: From Scientific Discovery to Commercial Launch The journey from scientific discovery to a commercial pharmaceutical or biotech product is long, complex, and filled with potential challenges. Many innovative discoveries never make it to market—not...
by Jeffrey Wotton | Feb 20, 2026 | Biopharma Consultant, Biotech Consulting, Insights, Pharma Consulting
The Role of the Fractional Quality Leader in Emerging Biotech Companies Why Outsourced QA Leadership Is Becoming the Norm Emerging biotech companies face a familiar challenge: innovation is moving fast, but infrastructure often lags behind. As organizations transition...
by Jeffrey Wotton | Nov 5, 2025 | Biopharma Consultant, Biotech Consulting, Insights, Life Sciences, Pharma Consulting, Quality Control
Bridging Innovation and Compliance: How Biopharma Consultants Help Life Sciences Companies Scale Responsibly As life sciences companies push the boundaries of biotechnology and pharmaceutical innovation, the need for balance between scientific advancement and...
by Jeffrey Wotton | Jun 20, 2025 | Biopharma Consultant, Biotech Consulting, GMP Good Manufacturing Practices, Insights, Pharma Consulting, Quality assurance compliance consulting
The Value of Phase-Appropriate Quality Systems in Early-Stage Drug Development For early-stage biotech and pharmaceutical companies, one of the most common challenges is determining how much quality infrastructure is necessary during the earliest phases of...
